Navigation Links
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Date:7/20/2009

AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals, and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014  Millions of people suffer from neck and arm ... Recently the FDA approved the launch of a clinical ... device developed by Spinal Kinetics, which may offer relief to ... arm pain. Hospital for Special Surgery (HSS), the number one ... New York City and in the ...
(Date:9/17/2014)... Texas , Sept. 17, 2014  Lightbeam ... Direct Accountable Care Organization (Physician Direct ACO) to ... their physicians in providing better care while reducing ... Physician Direct Accountable Care Organization ... Network Services (OPNS). The OPNS mission is to ...
(Date:9/17/2014)... COLUMBUS, Ohio , Sept. 17, 2014 /PRNewswire/ ... Riverside Radiology and Interventional Associates announced today ... Systems to enhance its image sharing capabilities ... case of any network failures. In addition, the ... to help navigate disparate PACS systems to more ...
Breaking Medicine Technology:Cervical Disc Clinical Trial for People with Neck and Arm Pain Set to Begin at Hospital for Special Surgery 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3
... N.J., Oct. 27 Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc., filed a new drug application under Section ... (FFDCA) with the U.S. Food and Drug Administration (FDA) ... and 40 mg tablets.  Watson,s rosuvastatin zinc tablets are ...
... Oct. 27 Intrinsic Bioprobes today announced that ... issued US Patent 7,816,095 covering novel blood protein ... first of a series of patent applications that ... clinical utility. "The biomarkers were discovered ...
Cached Medicine Technology:Watson Confirms Crestor® Patent Challenge 2Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction 2
(Date:9/17/2014)... (PRWEB) September 17, 2014 A recent ... fiscal year 2010 revealed 3.2% of these patients developed surgical ... 2.4% labeled as superficial SSIs. The average difference for each ... after adjustments. , The study, conducted by Marin Schweizer, PhD, ... University of Iowa, found the treatment costs for the hospitals ...
(Date:9/17/2014)... In ongoing coverage of formulary exclusion ... (DBN) continues to find criticism surrounding the tactic. ... issue , CVS Caremark Corp. and Express Scripts ... cut more drugs than ever, but industry consultants ... likely to achieve. Despite finding the strategy problematic, ...
(Date:9/17/2014)... Representatives with Capitol Pain Institute ... Anti-Defamation League Event at the Four Seasons in Austin, Texas. ... an honor to be a sponsor for this great event,” ... Schocket went on to explain that the event, the Torch ... and members at the Four Seasons to honor Torch of ...
(Date:9/17/2014)... September 17, 2014 The Mount ... Westchester, Putnam and Dutchess Counties in New York, ... affiliation agreement with the Mount Sinai Health System, ... integrated and coordinated care for the communities they ... Mount Sinai and MKMG will work together to ...
(Date:9/17/2014)... Washington, DC (PRWEB) September 17, 2014 ... family history. Along with regular screening and examination, a ... In this episode of Epicure with the Chef ... GWMFA Urologist Dr. Paul Rusilko to prepare a delicious ... in our western diets that influence risk of prostate ...
Breaking Medicine News(10 mins):Health News:Three Ways to Minimize Costs Associated with Surgical Site Infections 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 3Health News:Capitol Pain Institute Sponsoring an Anti-Defamation League Event & Awards Dinner 2Health News:Mount Sinai Health System Partners with Mount Kisco Medical Group to Enhance Health Care Options for Residents of Lower Hudson Valley 2Health News:Mount Sinai Health System Partners with Mount Kisco Medical Group to Enhance Health Care Options for Residents of Lower Hudson Valley 3Health News:Boost Prostate Health with Epicure with the Chef MDs 2
... , , WEDNESDAY, Nov. 14 (HealthDay News) -- During a ... drugs to be sold by pharmacists without a prescription, ... for and against the proposal by representatives of various ... day,s end, the FDA officials said they weren,t ready ...
... a,statement from Jeff Levi, Executive Director of Trust ... (TFAH) urges Congress to override the,President,s veto of ... Agencies Appropriations bill., The Labor/HHS bill provides ... states, territories, localities and hospitals to prepare for,public ...
... Kalamazoo, Mich.-based,Stryker Corporation and its former outpatient ... pay the United States $16.6,million to settle ... and other federal health care programs, the ... allegations that Physiotherapy, which is based,in Memphis, ...
... announced today,that the U.S. Food and Drug ... beta) for the treatment of anemia,associated with ... patients,on dialysis and patients not on dialysis. ... (CKD). MIRCERA is the only FDA-approved,erythropoiesis-stimulating agent ...
... Conference Call Scheduled for November 20, NAPA, Calif., ... specialty life sciences company engaged in the,study of senescense, ... skincare,and dermatological therapeutics today announced financial results for the,quarter ... quarter 2007 were $469,000 compared to,$2,027,000 for the same ...
... Natural Nutrition,(OTC Bulletin Board: NNTN) ( http://www.naturalnutritioninc.com ) ... of 10-QSB. Chris Mathers, CFO of,Natural Nutrition said, ... filing for Natural Nutrition will not be filed ... record revenue of $12.644,million and record EBITDA of ...
Cached Medicine News:Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 3Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 4Health News:Stryker Corp. & Physiotherapy Associates to Pay U.S. $16.6 Million for Alleged False Claims to Federal Health Care Programs 2Health News:FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing 2Health News:FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing 3Health News:Senetek PLC Reports Third Quarter 2007 Financial Results 2Health News:Senetek PLC Reports Third Quarter 2007 Financial Results 3Health News:Natural Nutrition to Report Record Revenue and EBITDA in Late Filing of 10-QSB 2
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... Aspen® CTO combines highly effective immobilization of ... a level of comfort that makes it ... substantially progressive immobilization in going from a ... and then on to a four-post orthosis. ...
... Shoulder Immobilizer with Contoured ... Navy cotton sling with foam-padded ... body straps. Quick-release closure buckles. ... 35 covered abduction wedge to ...
The Humeral Stabilizing System is a terrific option for immobilization of stable humeral fractures, stablesupracondular fractures, and biceps/triceps repairs....
Medicine Products: